Omnipaque injection 350mg I/ml Malta - English - Medicines Authority

omnipaque injection 350mg i/ml

ge healthcare as nycoveien 1, no-0485 oslo, norway - iohexol - solution for injection - iohexol 350 mg i/ml - contrast media

Optiray 240 mg I/ml solution for injection or infusion Ireland - English - HPRA (Health Products Regulatory Authority)

optiray 240 mg i/ml solution for injection or infusion

guerbet - ioversol - solution for injection/infusion - 240 mg i/ millilitre(s) - watersoluble, nephrotropic, low osmolar x-ray contrast media; ioversol

Optiray 240 mg I/ml PFS solution for injection Ireland - English - HPRA (Health Products Regulatory Authority)

optiray 240 mg i/ml pfs solution for injection

guerbet - ioversol - solution for injection - 240 mg i/ millilitre(s) - watersoluble, nephrotropic, low osmolar x-ray contrast media; ioversol

Optiray 300 mg I/ml solution for injection or infusion Ireland - English - HPRA (Health Products Regulatory Authority)

optiray 300 mg i/ml solution for injection or infusion

guerbet - ioversol - solution for injection/infusion - 300 mg i/ millilitre(s) - watersoluble, nephrotropic, low osmolar x-ray contrast media; ioversol

Optiray 300 mg I/ml PFS solution for injection Ireland - English - HPRA (Health Products Regulatory Authority)

optiray 300 mg i/ml pfs solution for injection

guerbet - ioversol - solution for injection - 300 mg i/ millilitre(s) - watersoluble, nephrotropic, low osmolar x-ray contrast media; ioversol

Optiray 320 mg I/ml solution for injection or infusion Ireland - English - HPRA (Health Products Regulatory Authority)

optiray 320 mg i/ml solution for injection or infusion

guerbet - ioversol - solution for injection/infusion - 320 mg i/ millilitre(s) - watersoluble, nephrotropic, low osmolar x-ray contrast media; ioversol

Optiray 350 mg I/ml solution for injection or infusion Ireland - English - HPRA (Health Products Regulatory Authority)

optiray 350 mg i/ml solution for injection or infusion

guerbet - ioversol - solution for injection/infusion - 350 mg i/ millilitre(s) - watersoluble, nephrotropic, low osmolar x-ray contrast media; ioversol

Optiray 350 mg I/ml PFS solution for injection Ireland - English - HPRA (Health Products Regulatory Authority)

optiray 350 mg i/ml pfs solution for injection

guerbet - ioversol - solution for injection - 350 mg i/ millilitre(s) - watersoluble, nephrotropic, low osmolar x-ray contrast media; ioversol

Synjardy European Union - English - EMA (European Medicines Agency)

synjardy

boehringer ingelheim - empagliflozin, metformin - diabetes mellitus, type 2 - drugs used in diabetes - synjardy is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients inadequately controlled on their maximally tolerated dose of metformin alone;in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin;in patients already being treated with the combination of empagliflozin and metformin as separate tablets.

ORALTAG- iohexol for solution United States - English - NLM (National Library of Medicine)

oraltag- iohexol for solution

interpharma praha, a.s. - iohexol (unii: 4419t9mx03) (iohexol - unii:4419t9mx03) - iodine 4.5 g - oraltag is indicated for use in computed tomography of the abdomen and pelvis to opacify bowel loops and delineate between normal loops and adjacent organs or areas of suspected pathology. limitations of use oraltag is not indicated for diagnostic examination of the gastrointestinal tract. oraltag is contraindicated in patients with a known hypersensitivity to iodinated contrast agents, including iohexol [see warnings and precautions (5.2)] . risk summary there are no human data on risks associated with the use of oraltag during pregnancy. the background risk in the u.s. general population of major birth defects is 2% to 4% and risk of miscarriage is 15% to 20% of clinically recognized pregnancies. in animal reproduction studies, no evidence of fetal harm was observed with intravenous administration of iohexol to rats and rabbits at doses up to 100 times the maximum recommended human intravenous dose. risk summary iohexol administered intravenously is present in human